title: Untreated or drug-treated tumor cells are differentially recognized by allogeneic lymphocytes.
abstract: Murine tumor cells treated with triazene compounds (TZC), in vivo or in vitro, are capable of eliciting specific transplantation resistance in syngeneic hosts, and T-cell-mediated proliferative and cytotoxic responses, directed against novel drug-induced antigen(s). Since this phenomenon, referred to as chemical xenogenization (CX) could open up new perspectives in the immunochemotherapy of human neoplasias, it was of interest to investigate whether CX could also occur in human tumors. However, established human tumor cell lines along with fully immunocompetent autologous lymphocytes, are seldom available. Therefore studies were carried out to test whether parental or TZC-treated tumor cells could be differentially recognized by allogeneic lymphocytes. Experiments were performed in both human and murine models, using a lung adenocarcinoma line treated in vitro with TZC, or an established xenogenized mouse lymphoma, respectively. The results indicate that allogeneic cytotoxic T-lymphocytes (CTL) recognize specifically murine TZC-treated tumor cells. This was supported by the finding that antisera directed against the drug-treated cells abrogated the generation and the cytolytic activity of allogeneic CTL reactive against the TZC-treated tumor. In addition it was found that changes of the antigenic pattern of cell membrane recognizable by cloned allogeneic CTL occur in the TZC-treated human carcinoma cell line.
authors.affiliation: Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy.
authors.forename: S
authors.initials: S
authors.lastname: D'Atri
authors.forename: L
authors.initials: L
authors.lastname: Romani
authors.forename: E
authors.initials: E
authors.lastname: Bonmassar
authors.forename: U
authors.initials: U
authors.lastname: Grohmann
authors.forename: M
authors.initials: M
authors.lastname: Tricarico
authors.forename: S E
authors.initials: SE
authors.lastname: Christmas
authors.forename: M
authors.initials: M
authors.lastname: Moore
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002999:Clone Cells; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D007940:Leukemia L5178 / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014226:Triazenes / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D014226:Triazenes; C053777:1-4-(3-methyltriazeno)benzoic acid